MiR-125 Family in Cardiovascular and Cerebrovascular Diseases

Yang Wang1,2, Jing Tan3, Lu Wang1,2, Gaiqin Pei1,2, Hongxin Cheng1,2, Qing Zhang1,2, Shiqi Wang1,2, Chengqi He1,2, Chenying Fu4,5* and Quan Wei1,2*

1Department of Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, China, 2Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, China, 3Department of Ultrasound Medicine, Binzhou People’s Hospital, Binzhou, China, 4National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China, 5Aging and Geriatric Mechanism Laboratory, West China Hospital, Sichuan University, Chengdu, China

Cardiovascular and cerebrovascular diseases are a serious threat to the health of modern people. Understanding the mechanism of occurrence and development of cardiovascular and cerebrovascular diseases, as well as reasonable prevention and treatment of them, is a huge challenge that we are currently facing. The miR-125 family consists of hsa-miR-125a, hsa-miR-125b-1 and hsa-miR-125b-2. It is a kind of miRNA family that is highly conserved among different species. A large amount of literature shows that the lack of miR-125 can cause abnormal development of the cardiovascular system in the embryonic period. At the same time, the miR-125 family participates in the occurrence and development of a variety of cardiovascular and cerebrovascular diseases, including myocardial ischemia, atherosclerosis, ischemia-reperfusion injury, ischemic stroke, and heart failure directly or indirectly. In this article, we summarized the role of the miR-125 family in the development and maturation of cardiovascular system, the occurrence and development of cardiovascular and cerebrovascular diseases, and its important value in the current fiery stem cell therapy. In addition, we presented this in the form of table and diagrams. We also discussed the difficulties and challenges faced by the miR-125 family in clinical applications.

Keywords: cardiovascular and cerebrovascular diseases, mir-125, atherosclerosis, myocardial ischemia, ischemia-reperfusion, ischemic stroke, mesenchymal stem cell

INTRODUCTION

Cardiovascular disease is one of the leading causes of death in the world. A retrospective study from 204 countries around the world found that from 1990 to 2019, the total number of cardiovascular diseases increased from 271 million to 523 million, and the number of cardiovascular deaths increased from 12.1 million to 18.6 million (Roth et al., 2020). Therefore, we should actively explore the occurrence and development mechanism of cardiovascular disease, which is of great significance to alleviate the pressure of health system and improve the quality of life on a global scale.

Although it has been nearly 30 years since the first microRNA (miRNA) was discovered, the research on miRNA is still hot. Earlier studies found that miRNA expression was tissue-specific, that is, specific miRNAs were expressed only in specific cells or tissues (Lagos-Quintana et al., 2002). It was discovered that most miRNAs could be expressed in different organs or cells, and some of them were highly expressed among different species (Ludwig et al., 2016). Many studies have shown that miRNAs play an important regulatory role in the occurrence and development of diseases, and
| Reference                  | miRNA     | Target cells/tissues/orgs | Disease or phenotype | Intervention     | Experimental setting | Species | Target genes |
|----------------------------|-----------|---------------------------|----------------------|------------------|----------------------|---------|--------------|
| Li et al. (2018)           | miR-125   | H9c2                      | Oxidative stress     | H$_2$O$_2$       | In vitro             | Rat     | MMP2         |
| Gródecka-Szwajkiewicz et al. (2020) | miR-125 | Plasma                    | Premature birth      | N                | In vivo              | Human   | N            |
| Díaz et al. (2017)         | miR-125a  | Myocardial cells          | I/R injury           | I/R, Urocortin    | In vitro, In vivo    | Rat     | BRCA1, MAP3K12, XBP1, TAZ, CPT2, MTRF1, Bcl2, caspase-3 |
| Svensson et al. (2014)     | miR-125a  | HUVECs, Arterial endothelial cells, Carotid plaque | Endothelial cell proliferation and viability | Growth factors | In vitro             | Human   | N            |
| Maltrias et al. (2015)     | miR-125a  | Plasma                    | Acute ischemic stroke | N                | In vivo              | Human   | N            |
| Zhang and Niu, (2020)      | miR-125a  | Plasma                    | Carotid plaque       | N                | In vivo              | Human   | N            |
| Chen et al. (2018)         | miR-125a  | HUVECs                    | Oxidative stress     | H$_2$O$_2$       | In vitro             | Human   | TrxR1        |
| Ye et al. (2020)           | miR-125a  | VSMCs                     | AS, VSMCs proliferation and migration | High glucose | In vitro             | Rat     | HMGCR        |
| Li et al. (2020)           | miR-125a  | Plasma                    | Acute ischemic stroke | N                | In vivo              | Human   | N            |
| Hu et al. (2019)           | miR-125a-3p | VSMCs                  | VSMCs proliferation and migration | Carotid artery balloon injury, Platelet derived growth factor | In vitro, In vivo | Rat | MAPK1 |
| Wang et al. (2019b)        | miR-125a-5p | VSMCs                | AS                   | Oxidized low-density lipoprotein | In vitro | Human | CCL4 |
| Zhou et al. (2021)         | miR-125a-5p | VSMCs               | VSMCs proliferation, migration and invasion | High glucose | In vitro | Rat | EGFR |
| Hendgen-Cotta et al. (2017) | miR-125a-5p | Heart                   | I/R injury           | I/R, Nitrite     | In vivo | Mouse | N |
| Che et al. (2014)          | miR-125a-5p | Arterial endothelial cell | Aging                | N                | In vitro             | Mouse   | RTEF-1 |
| Galluzzo et al. (2021)     | miR-125a-5p | Serum                   | Advanced heart failure | N                | In vivo              | Human   | N |
| Gareri et al. (2017)       | miR-125a-5p | VSMCs, A10             | Carotid artery balloon injury | Carotid artery balloon injury | In vitro, In vivo | Rat | ETS-1 |
| Zheng et al. (2019)        | miR-125a-5p | VSMCs                   | VSMCs proliferation  | Platelet derived growth factor-BB, Vein graft | In vitro, In vivo | Rat | IRF1 |
| Zhaoin et al. (2019)       | miR-125a-5p | HUVECs                  | AS                   | Oxidized low-density lipoprotein | In vitro | Human | TET2 |
| Kipaisairatana et al. (2020) | miR-125a-5p | Serum                   | Posterior circulation stroke/Peripheral vertigo | N                | In vivo              | Human   | N |
| Tiett et al. (2017)        | miR-125a-5p | Plasma                  | Acute ischemic stroke | N                | In vivo              | Human   | N |
| Li et al. (2010)           | miR-125a-5p | HSV, b.END.3, VSMCs, NIH3T3 | Oxidized low-density lipoprotein | Oxidized low-density lipoprotein | In vitro, In vivo | Stroke-prone spontaneously hypertensive rats | PreproET-1 |
| Ke et al. (2019)           | miR-125a-5p | Hippocampal tissues      | I/R injury           | I/R              | Bioinformatics analysis | Rat | N |
| Wang et al. (2021)         | miR-125b  | VSMCs                   | Vascular smooth muscle cells proliferation | N                | In vitro             | Rat | AAMP, SRF |
| Nagpal et al. (2016)       | miR-125b  | Cardiac fibroblasts      | Myocardial fibrosis  | Angiotensin II, TGF-β2 | In vitro, In vivo | Human, Mouse | Apelin, PS3 |
| Xu and Fang, (2021)        | miR-125b  | Myocardial cells         | Diabetic cardiomyopathy/ Myocardial cell death | High glucose | In vitro, In vivo | Human, Rat | HK2, LDHA |

(Continued on following page)
| Reference          | miRNA   | Target cells/ tissues/organs | Disease or phenotype                      | Intervention                                                                 | Experimental setting | Species          | Target genes                                                                 |
|-------------------|---------|------------------------------|-------------------------------------------|------------------------------------------------------------------------------|----------------------|------------------|----------------------------------------------------------------------------|
| Zhang et al. (2021) | miR-125b | Myocardial cells             | Heart failure/ Cardiomyocyte apoptosis    | Transverse aortic constriction                                               | In vitro, In vivo    | Mouse            | Bak1                                                                         |
| Liang et al. (2018) | miR-125b | PC12                         | I/R injury                                | I/R, OGD                                                                    | In vitro             | Rat              | CK2a                                                                 |
| Cheng et al. (2015) | miR-125b | Immune cells                 | Aging                                     | N                                                                           | In vivo              | Human            | CCL4                                                                   |
| Sun et al. (2020)  | miR-125b | Cardiac fibroblasts          | AMI                                       | Circ-LAS1L overexpression vector N                                           | In vivo              | Human            | SFRP5                                                                  |
| Bie et al. (2016)  | miR-125b | miR-125b                     | Cardiac fibroblasts growth and activation | I/R injury                                                                  | In vitro, In vivo    | Transgenic mice  | P53, Bak1, TRAF6                                                          |
| Wang et al. (2014) | miR-125b | H9c2                         |                                              |                                                                              |                      |                  |                                                                           |
| Wen et al. (2014)  | miR-125b | VSMCs                        | VSMCs transdifferentiation and calcification | β-glycerophosphoric acid                                                   | In vitro             | Rat              | Ets1                                                                 |
| Cao et al. (2016)  | miR-125b | VSMCs                        | AS, VSMCs proliferation                    | Homocysteine, Methionine diet, MI, OGD, Co-culture                         | In vitro, In vivo    | Human, ApoE−/− mouse | DNMT3b                                                                 |
| Xiao et al. (2018) | miR-125b | MSCs, cardiomyocytes, ESoCs  | MI, Autophagic Flux                        |                                                                              | In vitro, In vivo    | Mouse            | P53                                                                 |
| Wong et al. (2012) | miR-125b | H9c2, Cardiomyocytes Plasma  | Coronary heart disease                     |                                                                              | In vitro, In vivo    | Human            | Lin28                                                                 |
| Fan et al. (2020)  | miR-125b | Bone marrow mesenchymal stem cells, H9c2 | MI                                      |                                                                              | In vitro, In vivo    | Mouse            | P53, Bak1                                                                  |
| Ding et al. (2015) | miR-125b | Myocardial cells             | AMI                                       | AMI, Adenoviruses containing RASSF1 siRNA, hypoxia                         | In vivo              | Rat              | RASSF1                                                                  |
| Zhu et al. (2018)  | miR-125b | Heart                        | Birth defects                             | Cardiac-specific miR-125b-1 KO                                             | In vivo              | Human, AMPKα1 KO mouse |                                                                           |
| Xiao et al. (2020) | miR-125b | Heart                        | Hypercholesterolemia, I/R injury           | Special Diet, I/R                                                          | In vitro, In vivo    | Rat              | N                                                                       |
| Deng et al. (2015) | miR-125b | Embryonic stem cells, E14TG2A | Birth defects                             | All-trans-retinoic acid                                                     | In vitro             | Mouse            | N                                                                       |
| Dufays et al. (2021) | miR-125b | Cardiac fibroblasts          | MI/Myocardial fibrosis                    | Myofibroblasts -specific AMPKα1 KO                                         | In vitro, In vivo    | Human, AMPKα1 KO mouse | Cx43                                                                   |
| Nazari-Shafii et al. (2020) | miR-125b | MSCs extracellular vehicles | N                                         |                                                                              | In vivo              | Human            | N                                                                       |
| Ben-Zvi et al. (2020) | miR-125b | Serum                        | Systolic heart failure                    |                                                                              | In vivo              | Human            | N                                                                       |
| Lee et al. (2015)  | miR-125b | Embryonic stem cells, H9 HT-22 | Embryonic stem cells maturation            |                                                                              | In vitro, In vivo    | Human, Mouse, Rat | ErbB4                                                                  |
| Chen et al. (2020) | miR-125b | HL-1, H9c2, Ventricular cardiomyocytes Plasma | AMI, I/R injury                          |                                                                              | In vitro, In vivo    | Mouse, Rat        | Baik1, Kif13                                                            |
| Bayoumi et al. (2018) | miR-125b | miR-125b                     | Acute myocardial infarction                |                                                                              | In vivo              | Human            | N                                                                       |
| Jia et al. (2016)  | miR-125b | Bone marrow mesenchymal stem cells, VSMCs, Aortic tissues | AS                                      |                                                                              | In vitro, In vivo    | Human            | Map4K4                                                                 |
| Lin et al. (2021)  | miR-125b | miR-125b                     | AS                                        |                                                                              | In vitro, In vivo    | Human            | LACTB                                                                  |
| Lu et al. (2016)   | miR-125b | miR-125b                     | AS                                        |                                                                              | In vitro, In vivo    | Human            | LACTB                                                                  |
sometimes even in different stages in the same disease. Many miRNAs were highly conserved between different species (Perge et al., 2017). In different species, this provides us with the possibility to study whether the same miRNA plays the same role in the same disease, including cardiovascular and cerebrovascular diseases. For example, in both early and late stages, miR-19a/19b could protect cardiomyocytes in mice after myocardial infarction (MI) (Gao et al., 2019). Therapeutic silencing miR-146b-5p improved cardiac remodeling in porcine and mouse model of MI (Liao et al., 2021). MiR-21 from exosomes in human cardiomyocytes could be used to treat MI injury models in mice (Qiao et al., 2019).

MiR-125 family is widely expressed in mammals and its sequence is highly conserved. It is composed of three homologs hsa-miR-125a, hsa-miR-125b-1 and hsa-miR-125b-2 (Sun et al., 2013). hsa-miR-125a was discovered to be located at 19q13, while hsa-miR-125b-1 was verified on chromosomes 11q23 and hsa-miR-125b-2 on chromosomes 21q21 (Rodriguez et al., 2004). The miR-125 family plays an important role in the growth and development of animals, as well as the occurrence and development of cancer (Kim et al., 2016; Wang et al., 2019a). In addition, the role of miR-125 in cardiovascular and cerebrovascular diseases cannot be ignored. This article will review the role and mechanism of miR-125 family in the occurrence and development of cardiovascular and cerebrovascular diseases, including the role of the miR-125 family in the development and maturation of cardiovascular system, the occurrence and development of cardiovascular and cerebrovascular diseases, and its value in the stem cell therapy. Furthermore, we presented this in the form of tables and diagrams (Table 1; Figures 1, 2). Finally, we also discussed the challenges faced by the miR-125 family in clinical applications in the future.

MIR-125 FAMILY AND THE MATURATION AND AGING OF CARDIOVASCULAR SYSTEM

It was reported that when miR-125b-1 was specifically knocked out in the mouse heart, the mortality rate of perinatal mice was as high as 60%. Even in the surviving mice, their hearts were hypertrophy to varying degrees, and the mitochondria of the cardiomyocytes of these mice experienced varying degrees of morphological changes and loss of function in terms of morphology and function (Chen et al., 2021). Coincidentally, overexpression of miR-125b-2 in mouse embryonic stem cells (ESCs) inhibited the differentiation of mouse ESCs into endoderm and ectoderm, but it did not affect mesoderm differentiation, self-renewal and proliferation of mouse ESCs (Deng et al., 2015). Since the mesoderm was the origin of heart development, this study also indirectly showed that miR-125b-2 may play a role in maintaining the normal development of the heart in early mouse embryos. If murine and human embryonic-stem-cell-derived cardiomyocytes (m/hESC-CMs) were co-cultured with endothelial cells or endothelial cell...
lysates, it could improve the maturity and increase the expression of cardiomyocyte maturation markers in m/hESC-CMs. The reason for this phenomenon was that four miRNAs targeting ErbB4, including miR-125b-5p, overexpressed in m/hESC-CMs during the period when they were co-cultured with endothelial cells (Lee et al., 2015). This was probably because miRNAs from endothelial cells were released in the form of cell vesicles and absorbed by m/hESC-CMs during the co-cultivation process, thus increasing the maturity of m/hESC-CMs.

In another study on human ESCs (Wong et al., 2012), researchers found that miR-125b was an important regulator of human ESCs differentiation and development (including myocardium). Overexpression of miR-125b led to early heart disease. The upregulation of transcription factors, GATA4 and Nkx2-5, accelerated the progress of human embryonic stem cell-derived myocardial precursors to the phenotype of embryonic cardiomyocytes. In recent years, with the popularization of second-generation sequencing technology, more and more studies have shown that when the body was in a damaged state, large numbers of miRNAs would be released into the circulatory system from the damaged part (Cheng et al., 2019). Therefore, when the myocardium was damaged, the miRNA in the blood could be used as a marker of heart damage to a certain extent (Akat et al., 2014). Dorota Gródecka-Szwajkiewicz et al. analyzed the miRNA profile of umbilical cord blood of the peripheral blood mononuclear cells during the delivery of term infants and preterm infants. Many angiogenesis related miRNAs, including miR-125, decreased significantly in cord blood miRNAs of preterm infants. This may increase the risk of abnormal development and function of the cardiovascular system after these premature infants reached adulthood (Gródecka-Szwajkiewicz et al., 2020).

With the continuous aging, various components in the cell will change, and the cell function will also degrade. The increased expression of miR-125a in arterial endothelial cells of aging mice could regulate angiogenesis by targeting RTEF-1 and regulating the expression of eNOS and VEGF. The low expression of miR-125a in endothelial cells may be the “youth code” that maintained the normal operation of endothelial cells (Che et al., 2014). In addition, compared with the immune cells of young people, miR-125b was lowly expressed in the elderly. The expression of CCL4 was negatively correlated with the expression of miR-125b. CCL4 was an important chemokine of immune cells, which may be one of the reasons why aging had lower immunity compared with young people (Cheng et al., 2015).

**MIR-125 FAMILY AND ISCHEMIA-REPERFUSION INJURY**

After analyzing GSE82146 in the GEO database, Hong Ke et al. found that miR-125a and miR-125b may be the key genes that mediate ischemia-reperfusion (I/R) damage (Ke et al., 2019). In another study on I/R injury, more than half of the changes in miRNA expression including miR-125a-3p occurred in the nitrite treatment group compared with the control group 30 min after myocardial ischemia and 5 min after reperfusion (Hendgen-Cotta et al., 2017). These studies showed the high sensitivity of miR-125 family to I/R injury, which also provided a favorable reference value for miR-125 family to evaluate the therapeutic effect of I/R injury in the future.NF-κB signal pathway is the key to mediate myocardial injury after I/R injury. Overexpression of miR-125b in I/R injured mice could effectively reduce I/R-induced cardiomyocyte apoptosis, caspase-3/7 and...
caspase-8 activities, and prevent the activation of NF-κB pathway after I/R injury (Wang et al., 2014). In the rat I/R injury model, \textit{miR-125b} could inhibit the expression of CK2α and regulate the CK2α/NADPH oxidation signal pathway to protect the rat brain from I/R damage directly (Liang et al., 2018).

In addition to directly targeting downstream mRNA for regulation, ceRNA bonded by miRNA and circRNA influence the expression of mRNA to produce regulation. Cheng Luo et al. found that the expression of circPVT1 in rats with I/R injury increased significantly. It could inhibit the expression of \textit{miR-125b} and \textit{miR-200a} by targeting them, increase cardiomyocytes apoptosis after I/R injury, and weaken their protective effect on heart muscles (Luo et al., 2021). \textit{MiR-125a}, together with \textit{miR-139} and \textit{miR-324}, could cooperate with urocortin to protect rat myocardium after I/R injury (Diaz et al., 2017). By targeting MAPK1, \textit{miR-125a-3p} could also inhibited intimal thickening and the function of vascular smooth muscle cells (VSMCs), thereby reducing the degree of restenosis (Hu et al., 2019). In addition, \textit{miR-125a} could participate in the proliferation of endothelial cells by acting on Bcl2, caspase-3 and TrxR1 \textit{in vitro} experiments (Svensson et al., 2014; Chen et al., 2018). Interventional therapy is the traditional treatment for vascular stenosis. However, I/R injury and restenosis after interventional therapy have always been a major problem for clinicians. All the above studies provide potential targets for the treatment of I/R injury and vascular restenosis after injury from the gene level.

**MIR-125 FAMILY AND MYOCARDIAL ISCHEMIA**

Currently, the number of studies of \textit{miR-125b} is the most among miRNAs related to myocardial ischemia in the \textit{miR-125} family. Researchers found that the expression of \textit{miR-125b} in the plasma of coronary heart disease patients was lower than that of non-coronary heart disease patients. As the Gensini score increased, the level of \textit{miR-125b} reduced significantly (Ding et al., 2015). Diabetic cardiomyopathies is a special type of heart disease. \textit{miR-125b} and \textit{miR-34a} could protect cardiomyocytes in high glucose environment. Their action on the HK2 in glucose metabolism and LDHA in lactate metabolism respectively inhibited the glucose metabolism, glucose uptake and lactate metabolism of cardiomyocytes (Xu and Fang, 2021).

Hypercholesterolemia is one of the causes of myocardial ischemia. Ischemic preconditioning could up-regulate the expression of \textit{miR-125b-1-3p} and activate cardiac self-protection mechanisms. However, rats with hypercholesterolemia could attenuate the up-regulation of \textit{miR-125b-1-3p} level through ischemic preconditioning, which was related to the loss of cardioprotection (Szabó et al., 2020). Myocardial infarction (MI) is one of the main types of myocardial ischemia. Accurate and timely diagnosis of acute myocardial infarction (AMI) is particularly important for a good prognosis of patients. After analyzing the plasma miRNA data of AMI patients, it was found that \textit{miR-125b-5p} and \textit{miR-30d-5p} could be used to diagnose AMI effectively. Compared with the existing diagnostic methods of CK-MB, cTnI and myoglobin, the diagnostic performance of miRNA could be comparable to or even exceed the potential of existing diagnostic indicators (Jia et al., 2016). All of these contribute a new idea to the diagnosis of myocardial ischemia in our clinical work. Cardiomyocyte apoptosis is a common pathological process after myocardial ischemia. Up-regulation of \textit{miR-125b} in cardiomyocytes could reduce the protein levels of apoptosis-related markers c-caspase-3 and Bax significantly, and increase the expression of anti-apoptotic protein Bcl-2 to increase the survival rate of cardiomyocytes (Zhang et al., 2021). In addition, \textit{miR-125b} could also inhibit cardiomyocytes apoptosis by inhibiting the expression of RASSF1 and KLF3 (Bayoumi et al., 2018; Xiaochuan et al., 2020). lncRNA is another non-coding RNA which has the similar function with circRNA. It can form ceRNA with miRNA to weaken the post-transcriptional modification effect of miRNA on mRNA. In H9C2 cells, lncRNA-XIST could form ceRNA with \textit{miR-125b} to affect the downstream HEK2 gene, which could weaken the cardioprotective effect of \textit{miR-125b} and result in cardiomyocytes damage (Fan et al., 2020).

Myocardial fibrosis is an important cause of decreased heart function after myocardial ischemia. When heart was injured, the Ang II-TGF-β axis could influence the expression of \textit{miR-125b}, and then inhibit the expression of apelin and p53, leading to the proliferation of fibroblasts and the conversion of fibroblasts to myofibroblasts. The final outcome of the increase in \textit{miR-125b} level was the occurrence of myocardial remodeling (Nagpal et al., 2016). The effect of \textit{miR-125a} did seem to be opposite to that of \textit{miR-125b}. Similarly, in H9C2 cells, \textit{miR-125a} mimics reduced the expression of MMP2 and the proliferation of it, while promoting its apoptosis. However, ln-HOTAIR could restore the expression of MMP2 by targeting \textit{miR-125a}. At the same time, it could also promote the proliferation and survival of H9C2 (Li et al., 2018). In cardiac fibroblasts from patients with AMI, circ-LAS1L could bind to \textit{miR-125b} to relieve the inhibitory effect on downstream SFRP5. Furthermore, it could inhibit the activation, proliferation and migration, and promote apoptosis of cardiac fibroblasts (Bie et al., 2016; Sun et al., 2020). Compared with WT mice, the MI model of AMPKα1 knocked out conditionally showed more severe myocardial remodeling. Interfering with AMPKα1 expression in fibroblasts could also reduce the expression of Cx43 protein significantly. However, deletion of AMPKα1 could only reduce the activity of Cx43 promoter by about 40%, which was inconsistent with the expression of Cx43 protein. By using a preliminary quantitative PCR microRNA array, the authors showed that AMPKα1, in addition to binding directly to Cx43, could perform post-transcriptional control of Cx43 by upregulating \textit{miR-125b} in its own absence (Dufays et al., 2021).

**MIR-125 FAMILY AND ATHEROSCLEROSIS**

As we all know, atherosclerosis (AS) is a chronic and complex disease involving multiple factors, and it is one of the main causes of coronary heart disease, myocardial ischemia, and cerebral infarction. By comparing the miRNA in
symptomatic with asymptomatic atherosclerotic plaques after surgical resection Pierre Maitrias et al. found that miR-125a was significantly different between the two groups (Maitrias et al., 2015). This implies that miR-125a plays an important role in the changes of atherosclerotic plaques at different stages of the disease. Macrophages are important participants in the AS process. It is of great significance to reduce the aggregation of macrophages and protect damaged endothelial cells from inflammation in the control of AS. MCP-1 is an important chemokine for macrophages. In THP-1 macrophage cell line, miR-125b-5p could inhibit the expression of MCP-1 by targeting LACTB and attenuate the chemotaxis of macrophages (Lu et al., 2016). Pyroptosis is a new mode of programmed cell death that has been discovered and confirmed in recent years, and its development is often accompanied the release of massive inflammatory factors. TET2 was an important member of the TET enzyme family and played an important role in epigenetics (Shen et al., 2018). After treating the endothelial cell surface with oxLDL in vitro, the increased expression of miR-125a-5p could reduce the expression of TET2. Inactivation of TET2 could result in abnormal DNA methylation, NF-kB nuclear transposition, inflammatory response, and subsequent pyroptosis (Zhaolin et al., 2019).

With the development of the disease, VSMCs subjected to inflammatory stimulation will proliferate, migrate, and invade. This is one of the causes of plaque formation, arterial calcification, and stenosis. As we mentioned before, miR-125b had a targeting relationship with CCL4 (Cheng et al., 2015). Interestingly, in VSMCs, miR-125a also had a targeting relationship with CCL4. This combination could inhibit the expression of NLRP3 and alleviate the inflammatory process. After the VSMCs transfected with miR-125b mimics, they could resist inflammatory factors. TET2 was an important member of the TET enzyme family and played an important role in the maintenance of vascular homeostasis (Shen et al., 2018). After treating the endothelial cell surface with oxLDL in vitro, the increased expression of miR-125a-5p could reduce the expression of TET2. Inactivation of TET2 could result in abnormal DNA methylation, NF-kB nuclear transposition, inflammatory response, and subsequent pyroptosis (Zhaolin et al., 2019).

MIR-125 FAMILY AND OTHER CARDIOVASCULAR AND CEREBROVASCULAR DISEASES

At present, many of the cardiovascular and cerebrovascular patients would develop heart failure gradually as the diseases progress (Sulo et al., 2020). In patients with heart failure, the expression of miR-125b would rise significantly (Ben-Zvi et al., 2020). And in patients with advanced heart failure, there were significant differences in the expression of three miRNAs including miR-125a-5p, which were related to the composite end point of cardiac death, cardiac transplantation, or mechanical circulatory support implantation (Galluzzo et al., 2021). These studies had important predictive reference value for the prognosis of patients with heart failure.

In terms of pathogenesis, there are many similarities between ischemic stroke and myocardial ischemia. For example, in addition to being a marker of myocardial ischemia, the miR-125 family could also be used as a potential biomarker for acute vertigo, posterior circulation stroke and acute ischemic stroke (Tiedt et al., 2017; Kijpaisalratana et al., 2020). In a large case-control study (210 participants in the control group, 210 participants in the acute ischemic stroke group), the researchers found that the expression of miR-125a decreased in the plasma of the experimental group. The reason for this decline was that Inc-NEAT1 inhibited its expression (Li et al., 2020). The other Inc-ITSN1-2 inhibited the expression of miRNA such as miR-125a via inactivating its anti-angiogenesis and anti-inflammatory effects. The ultimate result was changes in alter vascular structure as well as inflammation related NF-kB pathway and TRL pathway activation (Zhang and Niu, 2020). In addition, the reduction of miR-125a-5p and miR-125b-5p expression was also related to the expression of preproET-1 in the aorta of stroke-susceptible spontaneous hypertensive rats (SHR-SPs) (Li et al., 2010). This provided new and strong evidence for the miR-125 family to participate in the maintenance of vascular homeostasis in the body. In the process of ischemic stroke, circ-UCK2 could act as an endogenous miR-125b-5p sponge to inhibit the activity of miR-125b-5p, which in turn led to an increase in GDF11 expression and improved neuronal damage subsequently (Chen et al., 2020).

MIR-125 AND MESENCHYMAL STEM CELLS AND THEIR EXTRACELLULAR VESICLES

The current treatments for cardiovascular and cerebrovascular diseases, such as interventions and drugs, have certain therapeutic effects. However, in many cases, conventional treatments cannot save the dying tissues. Mesenchymal stem cells (MSCs) are a kind of stem cells with multiple differentiation potentials and a promising treatment for cardiovascular and cerebrovascular diseases. By far, stem cell therapy has been partially applied to the clinical work of cardiovascular and cerebrovascular diseases (Hu et al., 2011). miR-125b-5p was highly expressed in the miRNA profiles of extracellular vesicles isolated from MSCs.
derived from cord blood and adipose tissues (Nazari-Shafti et al., 2020). This is the basis of MSCs and their vesicles in the treatment of cardiovascular and cerebrovascular diseases.

In the ApoE−/− mice model of AS, the researchers found that the exosomal miR-125b-5p from mouse bone marrow mesenchymal stem cells (BMSCs) inhibited the formation of atherosclerotic plaques by inhibiting the expression of Map4k4 (Lin et al., 2021). P53 was an important apoptosis-regulating gene in organisms, and it could regulate the apoptosis process of cells in a variety of ways (Hafler et al., 2019). Studies have found that transplantation of MSCs or their exosomes could effectively inhibit the autophagy flux, cell death and P53 gene expression of cardiomyocytes after MI. And the therapeutic effect of the MSCs-exosome group is significantly better than that of the MSCs-exosome-antimiR-125b group. Therefore, stem cells and their exosomes were likely to inhibit autophagy flux and target P53 through miR-125b, thereby inhibiting the apoptosis process of cardiomyocytes mediated by P53 gene and protecting cardiomyocytes (Xiao et al., 2018). It has been reported that when they were used to treat ischemic mouse body models, MSCs could improve their ability to promote functional angiogenesis after they were used to treat ischemic mouse body models, MSCs could improve their ability to promote functional angiogenesis after undergoing a hypoxia process (Huang et al., 2013). So, if the MSCs are pretreated with hypoxia, will their ability to treat cardiovascular and cerebrovascular diseases be improved? The answer is yes. MI mice treated with exosomes of BMMCs after 72 h of hypoxia culture had a significantly reduction in the area of MI. Next-generation sequencing showed that hypoxia treatment could significantly increase the content of miR-125b-5p in exosomes of BMMCs, and this mechanism of action was due to the ability of miR-125b to inhibit the expression of pro-apoptotic genes P53 and BAK1 in cardiomyocytes (Zhu et al., 2018). This study proved the highly effective treatment effect of miR-125 family members on MI again.

CONCLUSION

More and more studies have shown that miR-125 family is related to the development and differentiation of mammalian embryonic heart. Furthermore, they were found playing an important role in diseases and pathophysiological processes such as, coronary heart disease, MI, I/R injury, stroke, myocardial fibrosis, endothelial cell injury and myocardial cell apoptosis. However, in different diseases and different pathological processes, the same miR-125 family members play different roles. That is very interesting. For example, overexpression of miR-125b in cardiomyocytes can inhibit cardiomyocyte apoptosis and inflammatory response in pathological state to protect cardiomyocytes. But at the same time, miR-125b is also a regulator of cardiac fibrosis. Its overexpression in cardiac fibroblasts can enhance their proliferation and reduce their apoptosis. Therefore, excessive miR-125b will aggravate myocardial fibrosis and myocardial remodeling under pathological conditions, destroy the original morphological structure of the heart, increase the difficulty of neovascularization, and aggravate the apoptosis of cardiomyocytes in the damaged area.

As mentioned above, if miR-125 is used as a treatment target of cardiovascular and cerebrovascular diseases in clinical practice, further studies have to take the following two points into account. Firstly, because some miR-125 family members have ‘two sides’ in the role of cardiovascular and cerebrovascular diseases, we should find the best ‘balance point’ between harmful and beneficial to give full play to its maximum treatment and circumvent its negative effects. Secondly, in the future, it may not be enough to only study the optimal therapeutic dose of miR-125 in the process of diagnosis and treatment. It is also necessarily need to find a suitable miR-125 vector that can target our target cells for “precision treatment”. Only in this way can we give full play to the optimal therapeutic effect of miR-125 family members.

AUTHOR CONTRIBUTIONS

YW, CF and QW designed and wrote the manuscript. LW, GP, HC, QZ, SW and CH revised the manuscript. JT drew the figures. CF and QW provided critical feedback and helped to shape the manuscript. All authors listed have made a substantial contribution to the work.

FUNDING

The study was funded by National Key R&D Program of China (Grand No. 2020YFC2008502) and 1-3-5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.
Huang, C.-C., Chen, D.-Y., Wei, H.-J., Lin, K.-J., Wu, C.-T., Lee, T.-Y., et al. (2013). Hypoxia-induced Therapeutic Neovascularization in a Mouse Model of an Ischemic Limb Using Cell Aggregates Composed of HUVECs and cMBCs. Circulation 134 (37), 3941–9450. doi:10.1161/biomaterials.2013.09.010

Jia, K., Shi, P., Han, X., Chen, T., Tang, H., and Wang, J. (2016). Diagnostic Value of miR-30d-5p and miR-125b-5p in Acute Myocardial Infarction. Mol. Med. Rep. 14 (1), 184–194. doi:10.3892/mmr.2016.5246

Ke, H., Zhang, X., Cheng, L., Fan, Y., Xiao, M., Ma, Y., et al. (2019). Bioinformatic Analysis to Explore Key Genes Associated with Brain Ischemia-Reperfusion Injury in Rats. Int. J. Neurosci. 129 (10), 945–954. doi:10.1080/00207454.2019.1595615

Kijpaisalatrana, N., Nimsamer, P., Khamwut, A., Payungporn, S., Pisitkun, T., Chutinets, A., et al. (2020). Serum miRNA125a-5p, miR-125b-5p, and miR-433-5p as Biomarkers to Differentiate between Posterior Circulation Stroke and Peripheral Vertigo. BMC Neurol. 20 (1), 372. doi:10.1186/s12883-020-01946-3

Kim, K.-H., Seo, Y.-M., Kim, E.-Y., Lee, S.-Y., Kwon, J., Ko, J.-J., et al. (2016). The miR-125 Family Is an Important Regulator of the Expression and Maintenance of Maternal Effect Genes during Preimplantation Embryo Development. Open Biol. 6 (11), 160181. doi:10.1098/rsob.160181

Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., and Tuschl, T. (2002). Identification of Tissue-Specific MicroRNAs from Mouse. Curr. Biol. 12, 753–759. doi:10.1016/s0960-9822(02)00809-6

Lee, D. S., Chen, J.-H., Lundy, D. J., Liu, C.-H., Hwang, S.-M., Pabon, L., et al. (2015). Defined MicroRNAs Induce Aspects of Maturation in Mouse and Human Embryonic-Stem-Cell-Derived Cardiomyocytes. Cell Rep. 12 (12), 1960–1967. doi:10.1016/j.celrep.2015.08.042

Li, D., Yang, P., Xiong, Q., Song, X., Yang, X., Liu, L., et al. (2010). MicroRNA-125a/b-5p Inhibits Endothelin-1 Expression in Vascular Endothelial Cells. J. Hypertens. 28 (8), 1646–1654. doi:10.1097/01.jht.000032833a4922

Li, Z., Zhang, M., Chen, W., Wang, R., Ye, Z., Wang, Y., et al. (2018). LncRNA-HOAT1 Inhibition Aggravates Oxidative Stress-Induced H9c2 Cells Injury through Suppression of MMP2 by miR-125. Acta Biohim. Biophys. Sinica 50 (10), 996–1006. doi:10.1093/abbs/gmy102

Li, P., Duan, S., and Fu, A. (2020). Long Noncoding RNA NEAT1 Correlates with Higher Disease Risk, Worse Disease Condition, Decreased miR-124 and miR-125b and Predicts Poor Recurrence-free Survival of Acute Ischemic Stroke. J. Clin. Lab. Anal. 34 (2), e23056. doi:10.1002/jcla.23056

Liang, Y., Xu, J., Wang, Y., Yang, J.-Y., Yang, S.-L., Xiang, H.-G., et al. (2018). Inhibition of MiRNA-125b Decreases Cerebral Ischemia/Reperfusion Injury by Targeting CX20/NADPH Oxidase Signaling. Cell Physiol Biochem 45 (5), 1818–1826. doi:10.1159/000487873

Liao, Y., Li, H., Cao, H., Dong, Y., Gao, L., Liu, Z., et al. (2021). Therapeutic Silencing miR-146b-5p Improves Cardiac Remodeling in a Porcine Model of Myocardial Infarction by Modulating the Wound Reparative Phenotype. Protein Cell 13 (2), 194–212. doi:10.1007/s13238-020-00750-6

Lin, F., Zhang, S., Liu, X., and Wu, M. (2021). Mouse Bone Marrow Derived Mesenchymal Stem Cells-Septosed Exosomal microRNA-125b-5p Suppresses Atherosclerotic Plaque Formation via Inhibiting Map4k4. Life Sci. 274, 112949. doi:10.1016/j.lfs.2021.112949

Lu, J.-B., Yao, X.-X., Liu, J.-C., and Hu, Y.-W. (2016). MicroRNA-125b-5p Attenuates Lipopolysaccharide-Induced Monocye Chemoattractant Protein-1 Production by Targeting Inhibiting LACTB in TPH1 Macrophages. Arch. Biochem. Biophys. 590, 64–71. doi:10.1016/j.abb.2015.11.007

Ludwig, N., Leidinger, P., Becker, B., Backes, C., Fehmohl, T., Pallach, C., et al. (2016). Distribution of miRNA Expression across Human Tissues. Nucleic Acids Res. 44 (8), 3865–3877. doi:10.1093/nar/gkw116

Luo, C., Ling, G.-x., Ge, L.-t., Feng, X., Xie, X.-y., Fang, C., et al. (2021). Circular RNA PVT1 Silencing Prevents Ischemia-Reperfusion Injury in Rat by Targeting microRNA-125b and microRNA-200a. J. Mol. Cell. Cardiol. 159, 80–90. doi:10.1016/j.yjcc.2021.05.019

Matriass, P., Metzing-De-Meulth, V., Massy, Z. A., M’Baye-Moutoulou, E., Reits, T., Caus, T., et al. (2015). MicroRNA Deregulation in Symptomatic Carotid Plaques. J. Vasc. Surg. 62 (5), 1245–1250. doi:10.1016/j.jvs.2015.06.136

Nagpal, V., Rai, R., Place, A. T., Murray, S. B., Verma, S. K., Ghosh, A. K., et al. (2016). MiR-125b Is Critical for Fibroblast-To-Myoﬁbroblast Transition and Cardiac Fibrosis. Circulation 133 (3), 291–301. doi:10.1161/CIRCULATIONAHA.115.018174
Perge, P., Nagy, Z., Decmann, A., Igaz, I., and Igaz, P. (2017). Potential Relevance of microRNAs in Inter-species Epigenetic Communication, and Implications for Disease Pathogenesis. *RNA Biol.* 14 (4), 391–401. doi:10.1080/15476286.2016.1251001

Qiao, L., Hu, S., Liu, S., Zhang, H., Ma, H., Huang, K., et al. (2019). miR-125 in Cardiovascular-Cerebrovascular Diseases. *Frontiers in Cell and Developmental Biology* | www.frontiersin.org December 2021 | Volume 9 | Article 799049

Wen, P., Cao, H., Fang, L., Ye, H., Zhou, Y., Jiang, L., et al. (2014). miR-125b/Ets1 axis regulates Cardiac Fibroblast Activation, Growth, and Migration during 2000-2009. *Scand. J. Public Health* 14 (4), 391–395. doi:10.1177/1403498129829333

Sun, Y.-m., Zhao, J. c., Ge, X. m., Zhang, H., Wang, C. m., and Bie, Z. d. (2020). Circ_LAS1L regulates Cardiac Fibroblast Activation, Growth, and Migration through miR-125b-5p/SFRP5 pathway. *Circ. Res.* 123 (5), 564–578. doi:10.1161/HJH.0121.028021

Shen, Q., Zhang, H., Ma, H., Huang, K., et al. (2017). RNA-seq identifies circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as potential Biomarkers for Acute Ischemic Stroke. *Circ. Res.* 121 (8), 970–980. doi:10.1161/CIRCRESAHA.117.311572

Tiedt, S., Prestel, M., Malik, R., Schieferdecker, N., Duering, M., Kautsky, V., et al. (2017). mRNA-seq identifies circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as potential Biomarkers for Acute Ischemic Stroke. *Circ. Res.* 121 (8), 970–980. doi:10.1161/CIRCRESAHA.117.311572

Wang, J. K., Wang, Z., and Li, G. (2019). MicroRNA-125 in Immunity and Cancer. *Cancer Lett.* 454, 134–145. doi:10.1016/j.canlet.2019.04.015

Wang, J., Wu, Q., Yu, J., Cao, X., and Xu, Z. (2019). miR-125a-5p I-nhibits the E-xpression of NLRP3 by T-argeting CCL4 in H-uman V-ascula-S-mooth M-uscle C-ells Treated with ox-LDL. *Exp. Ther. Med.* 18 (3), 1645–1652. doi:10.3892/etm.2019.7717

Wang, X., Chen, S., Gao, Y., Yu, C., Nie, Z., Lu, R., et al. (2021). MicroRNA-125b-I-nhibits the P-roiferation of V-ascula-S-mooth M-uscle C-ells I-nduced by P-latelet-derived G-rowth F-actor B. *Exp. Ther. Med.* 22 (2), 791. doi:10.3892/etm.2021.10223

Wang, X., Ha, T., Zou, J., Ren, D., Liu, L., Zhang, X., et al. (2014). MicroRNA-125b Protects against Myocardial Ischemia/reperfusion Injury via Targeting PS3-Mediated Apoptotic Signalling and TRAF6. *Cardiovasc. Res.* 102 (3), 385–395. doi:10.1093/cr/vcu044

Wen, P., Cao, H., Fang, L., Ye, H., Zhou, Y., Jiang, L., et al. (2014). miR-125b/Betat axis regulates Transdifferentiation and Calcification of Vascular Smooth Muscle Cells in a High-Phosphate Environment. *Exp. Cell Res.* 322 (2), 302–312. doi:10.1016/j.yexcr.2014.01.025

Wong, S. S. Y., Ritter, C., Ramachandran, S., Aurgi, J., Pitt, C., Chandra, P., et al. (2012). miR-125b promotes early germ layer specification through Lin28/let-7d and Preferential Differentiation of Mesoderm in Human Embryonic Stem Cells. *PLoS one* 7 (4), e36121. doi:10.1371/journal.pone.0036121

Xiao, C., Wang, K., Xu, Y., Hu, H., Zhang, N., Wang, Y., et al. (2018). Transplanted Mesenchymal Stem Cells Reduce Atherosclerotic Flux in Infarcted Hearts via the Exosomal Transfer of miR-125b. *Circ. Res.* 123 (5), 564–578. doi:10.1161/CIRCRESAHA.118.312758

Xu, C.-r., and Fang, Q.-j. (2021). The Inhibition of Glucose by miR-34a and miR-125b protects against a mortality of Cardiomyocytes caused by Hypereglycemia. *Arquivos brasileiros de cardiologia* 116 (3), 415–422. doi:10.36660/abc.20190529

Ye, D., Lou, G. H., Li, A. C., Dong, F. Q., Chen, G. P., Xu, W. W., et al. (2020). MicroRNA-125a-mediated regulation of the M-valuate S-ignaling P-athway C-ontributes to H-igh G-lucose-induced P-roiferation and M-igation of V-ascula-S-mooth M-uscle C-ells. *Mol. Med. Rep.* 22 (1), 165–174. doi:10.8902/mmr.2020.11077

Zhang, B., Mao, S., Liu, X., Li, S., Zhou, H., Gu, Y., et al. (2021). miR-125b inhibits Cardiomyocyte apoptosis by targeting BAK1 in Heart Failure. *Mol. Med.* 27 (1), 72. doi:10.1016/j.molmed.2020.021-021328

Zhang, Y., and Niu, C. (2020). The Correlation of Long-Non-coding RNA Intersectin 1-T with Disease Risk, Disease Severity, Inflammation, and Prognosis of Acute Ischemic Stroke. *J. Clin. Lab. Anal.* 34 (2), e23053. doi:10.1111/jcla.12305

Zhaolin, Z., Jiaojiao, C., Peng, W., Yami, L., Tingting, Z., Jun, T., et al. (2019). OxLDL induces Vascular Endothelial Cell Pyroptosis through miR-125a-5p/TET2 pathway. *J. Cell Physiol.* 234 (5), 7475–7491. doi:10.1002/jcp.27509

Zhang, X., Wu, Z., Xu, K., Qiu, Y., Su, X., Zhang, Z., et al. (2019). Interfering Histone Deacetylase 4 Inhibits the Proliferation of Vascular Smooth Muscle Cells via Regulating MEG3/miR-125a-5p/IRF1. *Cell Adhes. Migrat.* 13 (1), 41–49. doi:10.1080/19336918.2018.1506653

Zhou, H., Lin, S., Hu, Y., Guo, D., Wang, Y., and Li, X. (2021). miR-125a-5p and miR-7 I-nhibits the P-roiferation, M-igation and I-nvasion of V-ascula-S-mooth M-uscle C-ell by T-argeting EGF. *Mol. Med. Rep.* 24 (4). doi:10.8902/mmr.2021.12347

Zhu, L.-P., Tian, T., Wang, J.-Y., He, J.-N., Chen, T., Pan, M., et al. (2018). Hypoxia-elicited Mesenchymal Stem Cell-Derived Exosomes Facilitate Cardiac Repair through miR-125b-Mediated Prevention of Cell Death in Myocardial Infarction. *Theranostics* 8 (22), 6163–6177. doi:10.7150/thno.28021

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Tan, Wang, Pei, Cheng, Zhang, Wang, He, Fu and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.